Anika Therapeutics (ANIK) Amortization of Deferred Charges (2019 - 2021)

Anika Therapeutics (ANIK) has reported Amortization of Deferred Charges for 3 consecutive years, with $400000.0 the latest figure, recorded in Q3 2021.

• On a quarterly basis, Amortization of Deferred Charges fell 2.68% year-over-year to $400000.0 in Q3 2021; TTM through Sep 2021 was $1.7 million, a 18.95% increase from a year earlier, with the FY2020 full-year figure at $1.5 million, up 29.86% from the prior year.
• Amortization of Deferred Charges was $400000.0 for Q3 2021 at Anika Therapeutics, down from $507000.0 in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $507000.0 in Q2 2021 and troughed at $289000.0 in Q3 2019.
• A 3-year average of $365636.4 and a median of $385000.0 in 2020 frame the typical range for Amortization of Deferred Charges.
• Across the five-year window, Amortization of Deferred Charges soared 42.21% in 2020 and declined 2.68% in 2021, its largest moves.
• Over 3 years, Amortization of Deferred Charges stood at $299000.0 in 2019, then jumped by 32.11% to $395000.0 in 2020, then rose by 1.27% to $400000.0 in 2021.
• The last three Amortization of Deferred Charges figures came in at $400000.0 (Q3 2021), $507000.0 (Q2 2021), and $405000.0 (Q1 2021), per Business Quant data.